Effect of exogenous fatty acids on diabetes neural/neurovascular complications

点击翻译按钮获取中文摘要

 DESCRIPTION (provided by applicant): Good glycemic control is the only recognized treatment for diabetic peripheral neuropathy (DPN) but studies have shown that it only slows progression. Therefore, other factors besides hyperglycemia must contribute to DPN, and there is a need for a better understanding of what these factors are in order to discover effective treatments. In the proposed studies we will test the hypothesis that different fatty acid classes have either a negative, neutral or positive effect on DPN. Lipids have been shown to be a major risk factor for diseases but there has been no comprehensive analysis of the effect of different classes of fatty acids on DPN. We will use novel rodent models of type 2 diabetes and manipulate diets so as to increase circulating and tissue levels of monounsaturated (MUFA) and polyunsaturated (PUFA) fatty acids. Specifically we will examine the potential negative, neutral or positive benefits of dietary enrichment with oleic acid (18:1, MUFA), linoleic acid (18:2, n-6 PUFA), γ-linolenic acid (18:3, n-6 PUFA), α-linolenic acid (18:3, n-3 PUFA) or eicosapentaenoic acid (20:5, EPA, n-3 PUFA) and docosahexaenoic acid (22:6, DHA, n-3 PUFA) on DPN and neurovascular function. The DPN endpoints will include determination of motor and sensory nerve conduction velocity and changes in the density and function of small sensory nerves in the skin and cornea. The latter endpoints will allow us to examine the effect of fatty acid dietary changes on nerve damage or repair. It is expected that supplementing diets of diabetic rodents with oils enriched in oleic acid (olive oil) or linoleic acid (safflower oil) will have little beneicial effect or may even exacerbate DPN and neurovascular dysfunction. Diets supplemented with γ- linolenic acid (evening primrose oil) or α-linolenic acid (flaxseed oil) are expected to be beneficial but to a lesser extent than diets supplemented with EPA and DHA, to be derived from menhaden (fish) oil. We propose that increasing dietary levels of n-3 PUFA (derived from flaxseed oil or menhaden oil) but not γ- linolenic acid (n-6 PUFA derived from evening primrose oil) will lower the n-6 to n-3 fatty acid ratio, a marker for reduced inflammation. Due to reduced ability in diabetes of conversion of α-linolenic acid to EPA we predict that increasing dietary levels of EPA and DHA but not α-linolenic acid will lead to an increased production of resolvins. Resolvins are produced from EPA and DHA by 15-lipoxygenase-1 (15-LOX-1) and have anti-inflammatory and neuroprotective properties. We propose that EPA and DHA treatment of rodents with type 2 diabetes will have the greatest impact on DPN through reducing inflammatory stress, improving neurovascular function and mediating nerve repair. We also propose that treating rodents with salicylsalicylic acid (salsalate) will increase tissue expressio of 15-LOX-1 leading to increased production of resolvins and even greater efficacy toward DPN and neurovascular complications when rodents with type 2 diabetes are treated with the combination of salsalate and menhaden oil. These preclinical studies will provide needed information to justify clinical trials for the treatment of DPN with fish oils and salsalate.